LH
VENTE TOTALE: 7 669 titres (~2 449 867,53 $ US)
- Insiders
- ANDERSON KERRII B, Schechter Adam H
- Total bought
- —
- Total sold
- $2,449,868
- Last activity
- 2026-08-17
- Last synced
-
2026-08-23 00:12:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-16
LH presents a mixed picture: moderate liquidity (65) is offset by weak fundamental trends (45), driven by persistent ROIC deterioration, elevated leverage (3.3x D/EBITDA), and an intangible-heavy balance sheet (56% of…
The first sentence of the analysis written for LH on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 26.8% | 27.9% | 27.7% | 31.3% | 38.0% | |
| Ebit Margin | 9.5% | 9.0% | 6.3% | 11.9% | 23.6% | |
| Ebitda Margin | 14.4% | 13.9% | 11.1% | 16.5% | 28.0% | |
| Operating Profit Margin | 10.9% | 8.4% | 6.0% | 12.1% | 23.2% | |
| Pretax Profit Margin | 7.9% | 7.4% | 4.7% | 10.4% | 22.0% | |
| Continuous Operations Profit Margin | 6.3% | 5.7% | 3.1% | 8.5% | 16.7% | |
| Net Profit Margin | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | |
| Bottom Line Profit Margin | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | |
| Current Ratio | 1.424 | 1.443 | 1.167 | 1.502 | 1.915 | |
| Quick Ratio | 1.235 | 1.295 | 1.020 | 1.349 | 1.771 | |
| Solvency Ratio | 0.160 | 0.135 | 0.113 | 0.181 | 0.293 | |
| Cash Ratio | 0.189 | 0.456 | 0.166 | 0.104 | 0.529 | |
| Price To Earnings Ratio | 23.803 | 25.795 | 47.352 | 14.408 | 10.982 | |
| Price To Earnings Growth Ratio | 1.282 | 0.303 | -0.720 | -0.336 | 0.204 | |
| Forward Price To Earnings Growth Ratio | 1.282 | 0.303 | -0.720 | -0.336 | 0.204 | |
| Price To Earnings Diluted Ratio | 23.985 | 25.941 | 47.650 | 14.491 | 11.072 | |
| Price To Earnings Diluted Growth Ratio | 1.309 | 0.304 | -0.724 | -0.339 | 0.207 | |
| Price To Book Ratio | 2.422 | 2.389 | 2.514 | 1.825 | 2.541 | |
| Price To Sales Ratio | 1.496 | 1.479 | 1.628 | 1.553 | 1.987 | |
| Price To Free Cash Flow Ratio | 17.308 | 17.556 | 22.648 | 12.502 | 9.853 | |
| Price To Operating Cash Flow Ratio | 12.724 | 12.133 | 14.911 | 9.422 | 8.394 | |
| Debt To Assets Ratio | 0.392 | 0.396 | 0.356 | 0.310 | 0.311 | |
| Debt To Equity Ratio | 0.836 | 0.903 | 0.756 | 0.619 | 0.617 | |
| Debt To Capital Ratio | 0.455 | 0.475 | 0.431 | 0.382 | 0.382 | |
| Long Term Debt To Capital Ratio | 0.401 | 0.398 | 0.340 | 0.333 | 0.345 | |
| Financial Leverage Ratio | 2.134 | 2.282 | 2.124 | 1.996 | 1.984 | |
| Working Capital Turnover Ratio | 10.438 | 12.902 | 11.656 | 5.796 | 5.718 | |
| Operating Cash Flow Ratio | 0.581 | 0.476 | 0.412 | 0.635 | 1.117 | |
| Operating Cash Flow Sales Ratio | 0.118 | 0.122 | 0.109 | 0.165 | 0.237 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.735 | 0.691 | 0.658 | 0.754 | 0.852 | |
| Debt Service Coverage Ratio | 1.938 | 1.323 | 0.968 | 3.576 | 14.001 | |
| Interest Coverage Ratio | 6.766 | 5.217 | 3.635 | 7.989 | 14.394 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.358 | 1.585 | 1.328 | 6.492 | 2,073.067 | |
| Operating Cash Flow Coverage Ratio | 0.228 | 0.218 | 0.223 | 0.313 | 0.490 | |
| Capital Expenditure Coverage Ratio | 3.776 | 3.237 | 2.927 | 4.059 | 6.754 | |
| Dividend Paid And Capex Coverage Ratio | 2.430 | 2.163 | 1.876 | 2.889 | 6.754 | |
| Dividend Payout Ratio | 0.275 | 0.326 | 0.608 | 0.153 | 0.000 | |
| Enterprise Value Multiple | 13.686 | 13.799 | 18.686 | 12.461 | 8.425 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 26.8% | ▼-1.1% | ▼-3.6% |
| Ebit Margin | 9.5% | ▲0.6% | ▼-2.5% |
| Ebitda Margin | 14.4% | ▲0.5% | ▼-2.4% |
| Operating Profit Margin | 10.9% | ▲2.5% | ▼-1.2% |
| Pretax Profit Margin | 7.9% | ▲0.6% | ▼-2.5% |
| Continuous Operations Profit Margin | 6.3% | ▲0.5% | ▼-1.8% |
| Net Profit Margin | 6.3% | ▲0.5% | ▼-2.6% |
| Bottom Line Profit Margin | 6.3% | ▲0.5% | ▼-2.6% |
| Current Ratio | 1.424 | ▼-0.019 | ▼-0.067 |
| Quick Ratio | 1.235 | ▼-0.061 | ▼-0.100 |
| Solvency Ratio | 0.160 | ▲0.025 | ▼-0.017 |
| Cash Ratio | 0.189 | ▼-0.268 | ▼-0.100 |
| Price To Earnings Ratio | 23.803 | ▼-1.993 | ▼-0.665 |
| Price To Earnings Growth Ratio | 1.282 | ▲0.980 | ▲1.136 |
| Forward Price To Earnings Growth Ratio | 1.282 | ▲0.980 | ▲1.136 |
| Price To Earnings Diluted Ratio | 23.985 | ▼-1.956 | ▼-0.643 |
| Price To Earnings Diluted Growth Ratio | 1.309 | ▲1.005 | ▲1.157 |
| Price To Book Ratio | 2.421 | ▲0.032 | ▲0.083 |
| Price To Sales Ratio | 1.496 | ▲0.017 | ▼-0.133 |
| Price To Free Cash Flow Ratio | 17.308 | ▼-0.248 | ▲1.334 |
| Price To Operating Cash Flow Ratio | 12.724 | ▲0.591 | ▲1.207 |
| Debt To Assets Ratio | 0.392 | ▼-0.004 | ▲0.039 |
| Debt To Equity Ratio | 0.836 | ▼-0.068 | ▲0.089 |
| Debt To Capital Ratio | 0.455 | ▼-0.019 | ▲0.030 |
| Long Term Debt To Capital Ratio | 0.401 | ▲0.003 | ▲0.037 |
| Financial Leverage Ratio | 2.134 | ▼-0.149 | ▲0.030 |
| Working Capital Turnover Ratio | 10.438 | ▼-2.465 | ▲1.136 |
| Operating Cash Flow Ratio | 0.581 | ▲0.105 | ▼-0.063 |
| Operating Cash Flow Sales Ratio | 0.118 | ▼-0.004 | ▼-0.033 |
| Free Cash Flow Operating Cash Flow Ratio | 0.735 | ▲0.044 | ▼-0.003 |
| Debt Service Coverage Ratio | 1.938 | ▲0.615 | ▼-2.423 |
| Interest Coverage Ratio | 6.766 | ▲1.549 | ▼-0.835 |
| Short Term Operating Cash Flow Coverage Ratio | 2.358 | ▲0.772 | ▼-414.608 |
| Operating Cash Flow Coverage Ratio | 0.228 | ▲0.010 | ▼-0.067 |
| Capital Expenditure Coverage Ratio | 3.776 | ▲0.539 | ▼-0.375 |
| Dividend Paid And Capex Coverage Ratio | 2.430 | ▲0.266 | ▼-0.793 |
| Dividend Payout Ratio | 0.275 | ▼-0.051 | ▲0.003 |
| Enterprise Value Multiple | 13.686 | ▼-0.113 | ▲0.274 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $20.87B | $19.24B | $19.80B | $18.43B | $26.10B | |
| Enterprise value | $27.54B | $24.99B | $25.21B | $24.35B | $30.97B | |
| EV / Sales | 1.97x | 1.92x | 2.07x | 2.05x | 2.36x | |
| EV / Op. cash flow | 16.79x | 15.76x | 18.99x | 12.45x | 9.96x | |
| EV / Free cash flow | 22.84x | 22.81x | 28.85x | 16.52x | 11.69x | |
| EV / EBITDA | 13.69x | 13.80x | 18.69x | 12.46x | 8.43x | |
| Net debt / EBITDA | 3.31x | 3.18x | 4.01x | 3.03x | 1.32x | |
| Current ratio | 1.42x | 1.44x | 1.17x | 1.50x | 1.92x | |
| Income quality | 1.87x | 2.13x | 3.50x | 1.95x | 1.31x | |
| Graham number | $157 | $139 | $99 | $187 | $242 | |
| Graham net-net | -$87 | -$83 | -$74 | -$88 | -$64 | |
| Tax burden | 79.1% | 77.7% | 73.5% | 103.4% | 82.3% | |
| Interest burden | 83.2% | 82.2% | 74.0% | 87.3% | 93.2% | |
| Working capital | $1.20B | $1.48B | $540.2M | $1.55B | $2.55B | |
| Invested capital | $14.66B | $14.38B | $12.94B | $13.59B | $17.06B | |
| Return on assets | 4.8% | 4.1% | 2.5% | 6.3% | 11.7% | |
| Operating ROA | 8.2% | 6.2% | 3.9% | 7.1% | 15.1% | |
| Return on tangible assets | 10.9% | 8.8% | 5.8% | 11.7% | 27.4% | |
| Return on equity | 10.2% | 9.3% | 5.3% | 12.7% | 23.1% | |
| Return on invested capital | 7.4% | 5.2% | 3.3% | 6.6% | 13.0% | |
| Return on capital employed | 9.7% | 7.2% | 5.4% | 8.4% | 17.3% | |
| Earnings yield | 4.2% | 3.9% | 2.1% | 6.9% | 9.1% | |
| Free cash flow yield | 5.8% | 5.7% | 4.4% | 8.0% | 10.1% | |
| Capex / Op. cash flow | 26.5% | 30.9% | 34.2% | 24.6% | 14.8% | |
| Capex / Depreciation | 63.8% | 76.1% | 78.6% | 89.7% | 79.8% | |
| Capex / Sales | 3.1% | 3.8% | 3.7% | 4.1% | 3.5% | |
| SG&A / Sales | 15.9% | 17.1% | 16.6% | 16.8% | 12.9% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.9% | 0.9% | 1.1% | 1.0% | 1.0% | |
| Intangibles / Total assets | 56.5% | 53.6% | 56.7% | 45.9% | 57.4% | |
| Days sales outstanding | 59d | 59d | 63d | 61d | 83d | |
| Days payables outstanding | 30d | 34d | 34d | 38d | 28d | |
| Operating cycle | 78d | 78d | 83d | 83d | 101d | |
| Cash conversion cycle | 48d | 44d | 48d | 44d | 73d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+8.5%EV / Sales ▲+2.8%EV / EBITDA ▼-0.8%EV / Op. cash flow ▲+1.029Earnings yield ▲+0.003Graham number ▲+18.143
Profitability
Return on equity ▲+0.009Return on assets ▲+0.007Return on invested capital ▲+0.022Return on capital employed ▲+0.025Operating ROA ▲+0.021Income quality ▼-0.257Tax burden ▲+0.014
Efficiency
Days sales outstanding ▲+0.307Days payables outstanding ▼-4.032Operating cycle ▲+0.222Cash conversion cycle ▲+4.255Capex / Sales ▼-0.007R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.019Net debt / EBITDA ▲+0.138Working capital ▼-279300000.000Invested capital ▲+283700000.000Intangibles / Total assets ▲+0.028
Change over 5 years
Valuation
Market cap ▼-20.0%EV / Sales ▼-16.3%EV / EBITDA ▲+62.4%EV / Op. cash flow ▲+6.830Earnings yield ▼-0.049Graham number ▼-85.709
Profitability
Return on equity ▼-0.130Return on assets ▼-0.069Return on invested capital ▼-0.056Return on capital employed ▼-0.076Operating ROA ▼-0.068Income quality ▲+0.562Tax burden ▼-0.032
Efficiency
Days sales outstanding ▼-23.611Days payables outstanding ▲+2.184Operating cycle ▼-22.504Cash conversion cycle ▼-24.688Capex / Sales ▼-0.004R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.492Net debt / EBITDA ▲+1.990Working capital ▼-1350600000.000Invested capital ▼-2393400000.000Intangibles / Total assets ▼-0.009
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-02-19 | Tony Wied | Purchase | $15,001 - $50,000 |
| 2026-02-11 | April Delaney | Purchase | $1,001 - $15,000 |
| 2026-02-04 | April Delaney | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-01-28 | April Delaney | Purchase | $1,001 - $15,000 |
| 2025-11-17 | April Delaney | Purchase | $1,001 - $15,000 |
| 2025-10-31 | April Delaney | Purchase | $1,001 - $15,000 |
| 2025-10-29 | April Delaney | Purchase | $1,001 - $15,000 |
| 2025-10-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-10-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-10-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-10-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-06-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-03-31 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-02-28 | John Delaney | Purchase | $1,001 - $15,000 |
| 2025-02-27 | John Delaney | Purchase | $1,001 - $15,000 |
| 2025-02-25 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-02-17 | John Delaney | Purchase | $1,001 - $15,000 |
| 2025-02-08 | John Delaney | Purchase | $1,001 - $15,000 |
| 2025-02-05 | John Delaney | Purchase | $1,001 - $15,000 |
| 2024-06-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-06 | John James | Sale (Full) | $1,001 - $15,000 |
| 2023-11-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-24 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-05-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-01-21 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2020-12-16 | Susie Lee | Sale (Full) | $1,001 - $15,000 |
| 2020-04-28 | Susie Lee | Purchase | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-01-09 | Mike Gallagher | Sale (Full) | $1,001 - $15,000 |
| 2018-09-05 | Bradley S. Schneider | Sale (Full) | $250,001 - $500,000 |
Recent news
- 2026-08-18 Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health Collaboration will support leadership development, practice improvement and innovation across the nation''s Community Health Centers BURLINGTON, N.C. and BETHESDA, Md.
- 2026-08-18 Labcorp (NYSE:LH) Sets New 12-Month High – Time to Buy? Shares of Labcorp Holdings Inc. (NYSE: LH - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $326.89 and last traded at $323.18, with a volume of 786484 shares changing hands. The stock had previously closed at $318.13. Analysts Set New Price Targets Several research analysts
- 2026-08-17 Labcorp to Host Investor Day on September 10, 2026 BURLINGTON, N.C., Aug. 17, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m.
- 2026-08-12 Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million The CEO liquidated 4,669 shares at a price of $320.37 per share, totaling ~$1.5 million on August 11, 2026. The transaction resulted in a 4% reduction of the executive''s total equity holdings in the company.
- 2026-08-10 Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich? LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.
- 2026-08-10 Here''s Why Labcorp Holdings (LH) is a Strong Momentum Stock Whether you''re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 2026-08-10 Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma Labcorp''s FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer BURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp''s PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.
- 2026-08-07 Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company''s five-year median.
- 2026-08-04 Here''s Why Labcorp Holdings (LH) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-08-04 Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche''s VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.